ELF3 and ovarian cancer: With the small molecule-based and CRISPR/Cas9 library-based screening platforms avaliable [26, 27], new therapeutic agents and signaling pathways that induce ELF3 expression, and subsequently improve ovarian cancer patient survival, can be identified.